{'fraction_non_alphanumeric': 0.0259222333000997, 'fraction_numerical': 0.009970089730807577, 'mean_word_length': 5.562091503267974, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Use of foridon in the treatment of arterial hypertension and hypertension of the lesser circulation].

Hypotensive effect of foridon was evaluated in 68 patients with first- and second-stage essential hypertension, 17 patients with renal hypertension and 18 patients with pulmonary hypertension. Changes in clinical condition, central hemodynamics, pulmonary arterial systolic pressure, inhalation and exhalation intensity were assessed. Foridon effect was shown to be largely due to reduced peripheral resistance. Foridon (30-60 mg) was effective in first-stage essential hypertension. In second-stage hypertension, foridon alone did not always produce an effect. In such cases, foridon-clofelin combination where clofelin hypotensive effect is enhanced can produce a marked hypotensive effect. Foridon is not indicated for the treatment of renal hypertension. Its use as part of combined treatment for chronic nonspecific pulmonary diseases where it is to reduce pulmonary hypertension, is justified.